Carolina I. Galaz-Montoya

Carolina I. Galaz-Montoya

Auto-generated profile, based on publicly available information

Carolina I. Galaz-Montoya

Pediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children’s Hospital, Phoenix, Arizona, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KJKatrine M. Johannesen
Katrine M. Johannesen
KAKhaing Phyu Aung
Khaing Phyu Aung
VLVivian W.Y. Liao
Vivian W.Y. Liao
NANathan L. Absalom
Nathan L. Absalom
HCHan C. Chua
Han C. Chua
PAPhilip K. Ahring
Philip K. Ahring
Disorders of GABRA3 , the only epilepsy-associated GABA A receptor subunit gene on the X chromosome, have eluded clinical clarity due to ambiguous inheritance patterns and variable phenotypes. The long-standing assumption that all pathogenic variants cause loss of function further obscured genotype–phenotype relationships and hindered progress. Here, we curated a cohort of individuals with a GABRA3 variant, integrating deep phenotyping, genotyping, family history, and electrophysiology with a targeted mouse model. Among 43 individuals with 19 GABRA3 variants, functional analyses revealed gain- and loss-of-function effects, each linked to distinct clinical profiles. Gain-of-function variants were associated with severe, treatment-resistant epilepsy and profound intellectual disability, disproportionately affecting males, who were often nonambulant and had cortical visual impairment. Loss-of-function variants produced milder phenotypes, with epilepsy rarely observed; affected males showed behavioral issues and language delay, while females were unaffected carriers. Our gain-of-function ( Gabra3 Q242L/+ ) mouse model mirrored these sex-specific differences, showing increased seizure susceptibility, early death, and marked cortical hyperexcitability. These insights resolve longstanding uncertainties surrounding GABRA3 and redefine how X-linked disorders are interpreted. They demonstrate that it is the functional impact of a variant, not its mere presence, that determines whether a condition manifests dominantly or recessively. This distinction carries important implications for genetic counseling, precision medicine, and the broader interpretation of X-linked neurodevelopmental disorders.

6 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PBPritha Bisarad
Pritha Bisarad
YWYung-Chun Wang
Yung-Chun Wang
PSPeter Skidmore
Peter Skidmore
CGCarolina I. Galaz-Montoya
Carolina I. Galaz-Montoya
SLSara A. Lewis
Sara A. Lewis
HDHossein Darvish
Hossein Darvish
Cerebral palsy (CP) is a neurodevelopmental disorder of motor function, with genetic etiologies, particularly de novo variants, identified in approximately one-third of cases. The contribution of consanguinity – long-recognized as a CP risk factor – has remained undefined. Here, we report findings from 188 primarily consanguineous Middle Eastern families with CP and identified putative causative genes in nearly three-quarters. The majority demonstrated recessive inheritance, although multi-level consanguinity and multilocus pathogenic variants complicated Mendelian assortment analyses. We identified 110 known CP-associated genes – five with phenotypic expansions and three others exhibiting new recessive inheritance patterns – and 24 novel candidates. We characterized ten candidates as high-confidence based on independent replication and protein modeling. We experimentally validated a role for SUCO variants in CP and newly identified a role for mid-gestational migrating excitatory neurons in the disorder. These findings highlight new genes, pathways, and phenotypes that reveal striking genomic diversity in CP.